Growth of s 1 lac invested on inception date. SIP Performance: Scheme Name 1 Yr 2 Yr 3 Yr 4 Yr 5 Yr. CNX Midcap
|
|
- Marylou Powell
- 5 years ago
- Views:
Transcription
1
2 BNP Paribas Midcap The investment objective of the is to seek to generate long-term capital appreciation by investing primarily in companies with high growth opportunities in the middle and small capitalization segment, defined as 'Future Leaders'. Mr. Shreyash Devalkar, PGDM, B.E, has over 7 years of experience in equity markets as an Research Analyst, managing this fund since October 11. Expense Ratio :.7% Inception Date : May, AAUM : s Crs Benchmark : NAV (Gr) : s 13. Avg Mkt Cap : s 1, crs Note: Avg market cap is based on available portfolio detail of 9% of equity holdings. Point to Point : Mth 1 Yr Yr 3 Yr Yr BNP Paribas Midcap (As on November 3, 13) Yr Yr 3 Yr Yr Yr BNP Paribas Midcap May Dec Sep 7 Jun BNP Paribas Midcap BNP Paribas Midcap Mar 9 Dec Sep Jun Mar 1 Dec Rs 1. Lacs Rs 1.3 Lacs Sep BNP Paribas Midcap Yr Yr 3 Yr Yr Yr - -1 Mth 1 Yr Yr 3 Yr Yr Calendar year wise : YTD BNP Paribas Midcap Standard Deviation.7 Sharpe. Beta.9 Treynor.39 Alpha. This fund has consistently delivered positive return across time frame from months to years. In last years when has delivered 19% return, this fund has given % return. Even on calender year basis this fund has outperformed index by wide margin except in 9. In last one year when market condition remained challenging with giving negative return, this fund has delivered 1% return. This fund is highly recommended to find a place in midcap fund portfolio of investors with its consistent benchmark beating performance. However due to inherent risk associated with mid cap and small cap stocks, this fund will witness volatility which investors should be ready to live with.
3 Birla SL Top 1 An Open Ended Growth Scheme which seeks to provide medium to long-term capital appreciation, by investing predominantly in a diversified portfolio of equity and equity related securities of top 1 companies as measured by market capitalization. Mr. Mahesh Patil, managing this fund since July 1, has over years of experience in fund management, equity research and corporate finance. Prior to joining BSLAMC, he has worked with Reliance Infocom Ltd. in Business Strategy. Expense Ratio :.% Inception Date : October, AAUM : s 3 crs Benchmark : NAV (Gr) : s 7. Avg Mkt Cap : s 1,1, crs Note: Avg market cap is based on available portfolio detail of 9% of equity holdings. Point to Point : Mth 1 Yr Yr 3 Yr Yr Birla SL Top Calendar year wise : Birla SL Top 1 Birla SL Top 1 Mth 1 Yr Yr 3 Yr Yr YTD Out performance across time frame makes this fund one of the strongly recommended large cap fund. Last year return of % compared to 1% return delivered by. For one year ended Nov 3th, this fund has given 9% return. One might be disappointed seeing this return which is just above bank account interest rate but when we compare this with return of % by its benchmark and return of.% by category average, this surely deserves applaud for the skills of the fund manager. (As on November 3, 13) 3 1 Oct Jun Mar 7 Dec 7 Birla SL Top 1 Birla SL Top 1 Sep Jun Strong history of over 11 years and consistent out performance, an ideal ingredient for any to be part of an investor's core portfolio. Strongly recommended large cap fund to be part of your core portfolio. Mar 1 Dec Sep Jun 1 Rs.7 Lacs Rs. Lacs 1 Yr Yr 3 Yr Yr Yr Birla SL Top 1 Standard Deviation. Sharpe.1 Beta 1. Treynor. Alpha. Mar Yr Yr 3 Yr Yr Yr Nov
4 Kotak Select Focus The investment objective of the is to generate long-term capital appreciation from a portfolio of equity and equity related securities, generally focused on a few selected sectors. Mr. Harsha Upadhyaya, managing this fund since August 1, has 1 years of rich experience spread over Equity Research and Management. AAUM : s 33 crs NAV (Gr) : s 13.7 Point to Point : Expense Ratio :.% Inception Date : Sep.11, 9 Benchmark : Avg Mkt Cap : s 1,7, crs Note: Avg market cap is based on available portfolio detail of 97% of equity holdings. 3 Mth Mth 1 Yr Yr 3 Yr Kotak Select Focus Kotak Select Focus (As on November 3, 13) Sep 9 Dec 9 Jun 1 Dec 1 Jun 11 1 Yr Yr 3 Yr Yr 1 Kotak Select Focus Kotak Select Focus Dec Jun Dec 1 Rs 1.3 Lacs Rs 1. Lacs Jun Nov Kotak Select Focus Mth Mth 1 Yr Yr 3 Yr 1 Yr Yr 3 Yr Yr Calendar year wise : Kotak Select Focus YTD Standard Deviation.31 Sharpe -. Beta.9 Treynor -.13 Alpha.9 Stable large cap oriented fund from Kotak fund house with consistence out performance record in last 3 years. Across time frame from 3 months to 3 years this fund has out performed it's benchmark CNX Nifty index. In 1 when Nifty delivered 7% this fund out performed Nifty by wide margin of % and delivered 33% return. Kotak Select Focus is a large cap oriented fund with 1% holding in large cap stocks and around 9% in mid cap stocks. has consistence out performing history but is relatively new fund with only years of history.
5 L&T India Special Situations The aims to invest in undervalued companies for long term investment with key theme focus being 'Special Situations' - these are situations that are out-of-the-ordinary and which therefore present interesting stock picking opportunities. Mr. Soumendra Nath Lahiri, PGDM - IIM Banglore, has over over 1 years of rich experience of which 17 years in equity investments and research, managing this fund since November 1. AAUM : s 7 Crs NAV (Gr) : s 1.7 Point to Point : Expense Ratio :.9% Inception Date : May, Benchmark : Avg Mkt Cap : s, crs Note: Avg market cap is based on available portfolio detail of 9% of equity holdings. Mth 1 Yr Yr 3 Yr Yr L&T India Special Situations L&T India Special Situations (As on November 3, 13) May Dec Sep 7 Jun L&T India Special Situations L&T India Special Situations Mar 9 Dec Sep Jun Mar 1 Rs.17 Lacs Rs 1.9 Lacs 1 Yr Yr 3 Yr Yr Yr L&T India Special Situations Dec Sep Yr Yr 3 Yr Yr Yr - Mth 1 Yr Yr 3 Yr Yr Calendar year wise : YTD L&T India Special Situations This fund has out performed both its benchmark index which is BSE and category average. This fund has relatively long history of 7 years and fund has delivered 11% CAGR since inception compared to 9% return of BSE index. In last 3 years when both benchmark as well as category average returns are negative this fund managed to deliver positive return. Standard Deviation. Sharpe -.1 Beta.9 Treynor -.3 Alpha.19 This fund follows investment strategy of investing in stocks which are 'out of flavor' and thus offers special situation of investing. Although this fund has consistently out performed over the years investors are advised to use this fund only as 'toppings' for their portfolio and not as core portfolio.
6 Mirae Asset India Opportunities To generate long term capital appreciation by capitalizing on potential investment opportunities through predominantly investing in equity and equity related securities. Mr. Gopal Agrawal, B.E.(Chemical), has over 1 years of experience in fund management and Mr. Neelesh Surana, B.E.(Mechanical), MBA(Fin), has over 17 years of experience in financial services including fund management. Both managing this fund since April. Expense Ratio :.% Inception Date : April, AAUM : s Crs Benchmark : NAV (Gr) : s 19.1 Avg Mkt Cap : s 1,, crs Note: Avg market cap is based on available portfolio detail of 93% of equity holdings. Point to Point : Mth 1 Yr Yr 3 Yr Yr Mirae Asset India Opp Calendar year wise : Mirae Asset India Opp. Mirae Asset India Opp YTD Mth 1 Yr Yr 3 Yr Yr This fund is clear out performer across time frame. In last years this fund has delivered 7% CAGR compared to 19% by its benchmark BSE and 19% by category average. On YTD basis in 13 when small and mid cap section of the market struggled this fund is up by.% against close to % of BSE and 1% return of category average. (As on November 3, 13) Apr Sep Mar 9 Sep 9 Mirae Asset India Opp. Mar 1 Mirae Asset India Opp. Sep Although relatively new fund with little over year history, this fund has done exceedingly well in years of existence. This fund has not only out performed in rising market but also has managed downside well. Strongly recommended multi cap fund to be part of investor's core portfolio. Mar 11 Sep Mar Sep 1 Rs 1.9 Lacs Rs 1.3 Lacs 1 Yr Yr 3 Yr Yr Yr Mirae Asset India Opp. Mar Yr Yr 3 Yr Yr Yr Sep Standard Deviation. Sharpe.1 Beta.9 Treynor. Alpha.
Systematic Investment Plan Report
s ICICI Prudential Focused Bluechip Equity Fund - Ret - Growth SBI Bluechip Fund - Growth Nifty 50 S&P BSE 100 3 Yr 180000 201294 723 184833 169 3 Yr 180000 207838 934 187449 259 5 Yr 300000 410356 1232
More informationSUMMARY TERM SHEET. Sl. Particulars Details 1. Issuer L&T Finance Holdings Limited (the Company / the Issuer / L&TFHL )
SUMMARY TERM SHEET Sl. Particulars Details 1. Issuer L&T Finance Holdings Limited (the Company / the Issuer / L&TFHL ) 2. Date of resolution May 28, 2014 passed by the Board of Directors authorizing the
More informationBANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-
BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest
More informationMay 6, 2008 First Quarter 2008 Results
SWEUB2227319CMDV7 May 6, 28 First Quarter 28 Results 1Q 28: Improved results in a challenging environment Page 2 Strong loan growth at 34.2% yoy Accelerated deposit growth at 31% yoy; improved loans /
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK
Small-Cap Research February 2, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive
More informationGrowth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts
Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at www.dbs.com/investor
More informationBeing the partner of choice. Beat Spalinger, CEO & President presenting at the 2011 Berenberg European conference
Being the partner of choice Beat Spalinger, CEO & President presenting at the 2011 Berenberg European conference Disclaimer This presentation contains certain forward-looking statements, which can be identified
More informationInterim Report 1 January September 2017
2014-01-01 2014-12 Interim Report 1 January 2017 30 September 2017 Cantargia AB 556791-6019 Cantargia refers to Cantargia AB (publ), corporate ID number 556791-6019. Clinical trial initiated Highlights
More informationNATIONAL BANK OF POLAND
NATIONAL BANK OF POLAND RECENT TRENDS IN THE REAL ESTATE MARKET INTERNATIONAL CONFERENCE THE HOUSING PRICES IN ROMANIA - recent developments - Ph.D. Andrei RĂDULESCU Senior Economist Researcher, IWE, Romanian
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationThird Quarter 2017 NCREIF Indices Review. Fall Conference November 7, 2017
Third Quarter 2017 NCREIF Indices Review Fall Conference November 7, 2017 Panelist Overview Jeff Fisher NCREIF Data & Research Consultant Sara Rutledge NCREIF Director of Research John Ehli Portfolio Manager
More informationCorcept Therapeutics, Inc.
March 20, 2015 Corcept Therapeutics, Inc. NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/20/2015 Current Price (03/19/15) $5.85 Target Price $6.25 (CORT-NASDAQ) SUMMARY
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK
Small-Cap Research September 12, 2014 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set
More informationResults Briefing. 15 ~ 17 May 2007
Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights
More information22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
More informationKansas EMS Naloxone (Narcan) Administration
Kansas EMS Naloxone (Narcan) Administration Executive Summary Kansas Board of Emergency Medical Services August 217 The following pages denote an ongoing trending of naloxone administration by Kansas Emergency
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationFourth Quarter 2017 NCREIF Indices Review February 9, 2018
Fourth Quarter 2017 NCREIF Indices Review February 9, 2018 Panelist Overview Jeff Fisher NCREIF Data & Research Consultant Doug Herzbrun Global Head of Research CBRE Global Investors Disclaimer Today we
More informationDabur India Limited. October 10, CMP (Rs.) 284. Key Developments
Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 s. Dabur India Limited. October 10, 2016 BSE Code: 500096 NSE Code: DABUR Reuters Code: DABU.NS Bloomberg Code:
More informationARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK. Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011
ARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011 STRUCTURE 1. National economy 2. International economy 3. Outlook 2 CENTRALE
More informationAn Updated Approach to Colon Cancer Screening and Prevention
An Updated Approach to Colon Cancer Screening and Prevention Kevin Liebovich, MD Director for Quality for Gastrointestinal diseases Advocate Condell Medical Center Colon Cancer Screening and Prevention
More informationPerrigo Company plc (PRGO-NYSE)
March 20, 2015 Perrigo Company plc (PRGO-NYSE) NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 09/02/2012 Current Price (03/19/15) $170.37 Target Price $179.00 SUMMARY
More informationNovo-Nordisk As (NVO-NYSE) Analyst Note
February 03, 2015 Novo-Nordisk As (NVO-NYSE) Analyst Note NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 02/10/2014 Current Price (02/02/15) $44.73 Target Price $47.00
More informationSmall-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK
Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final
More informationTandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile
Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business
More informationAltria Group Inc (MO-NYSE)
March 20, 2015 Altria Group Inc (MO-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Underperform Date of Last Change 08/12/2009 Current Price (03/19/15) $51.27 Target Price $54.00
More informationcommercial real estate
August 15 Asset Management Documeent title on one or two Defensive lines in Gustan investing Book in pt U.S. commercial real estate TIAA-CREF Global Real Estate Strategy & Research Martha Peyn, Ph.D. Managing
More informationH. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review
H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports
More informationInvestor Update May 2016
Investor Update May 2016 Novo Nordisk poised for growth through helping care for rising global diabetes epidemic On Marsico Capital Management s trip to Australia in March, Portfolio Managers Tom Marsico
More informationOrexigen Therapeutics, Inc.
February 27, 2015 Orexigen Therapeutics, Inc. Current Recommendation NEUTRAL Prior Recommendation Outperform Date of Last Change 06/06/2012 Current Price (02/26/15) $5.87 Target Price $6.25 SUMMARY DATA
More informationSingapore Exchange Limited 1Q FY2009 Financial Results
Singapore Exchange Limited 1Q FY2009 Financial Results 15 October 2008 Singapore Exchange 1 1Q FY2009 Financial Performance NPAT fell 35% from record 1Q FY2008 Operating profit flat compared to 4Q FY2008
More informationDabur India Ltd. BUY CMP (Rs.) 277 Target (Rs.) 344 Potential Upside 24% Investment Rationale. Volume No.. I Issue No. 40. September 8 th, 2015
Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15. Volume No.. I Issue No. 40. Dabur India Ltd. September 8 th, 2015 BSE Code: 500096 NSE Code: DABUR Reuters Code:
More information1Q 2014 Earnings Release
1Q 2014 Earnings Release April 2014 DISCLAIMER Financial results for 1Q 2014 are provisional and accordingly subject to change according to the outside independent auditors review. This presentation contains
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationIndustry experience in consortium i.e. from BEE party or non-bee partners
A. ENTREPRENEURSHIP FINANCE Imbewu Entrepreneurship Finance would provides risk capital to new businesses and to early stage businesses owned and managed by black people meeting the following criteria:
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationASL MARINE. DBS Vickers Pulse of Asia Roadshow 10 January 2012
ASL MARINE DBS Vickers Pulse of Asia Roadshow 10 January 2012 Presentation Outline Group Overview 1Q FY2012 Financial Review (3 months ended 30 September 2011) Operations Review - Shipbuilding - Shiprepair
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2018 Win-Partners Co., Ltd. (3183) 2Q results ending September 2017 Consolidated results summary ( mil)2q to Sep 2016 Sep 2017 YoY OE Sales 27,713 29,753 +7.4% 29,500 Operating
More informationMANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.
MANAGEMENT MGMT 0021 THE MANAGEMENT PROCESS 3 cr. An introduction designed to emphasize the basic principles, practices, and terminology essential to the understanding of contemporary business and its
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationVery good Q3 contribution from Vegetable Juices Inc.
2014 nine-month sales (1 st January to 30 September 2014) Very good Q3 contribution from Vegetable Juices Inc. Worldwide economic environment still adverse Sustained growth by Food & Beverage Press release
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More information1Q 2015 Results A Positive Start to 2015
1Q 2015 Results Main Events Operating Results Order Backlog Financial Performance Update on Disposal 1Q 2015 Results A Positive Start to 2015 Rome - May 14, 2015 1Q 2015 Main Backlog Events 1Q 2015 Results
More informationSleep Market Panel. Results for June 2015
Sleep Market Panel Results for June 2015 Notes: o This is a monthly trending report of panel member data along with additional analysis by: Sleep labs affiliated with Hospitals vs. Independent Labs o Hospital
More informationPROACTIVE INVESTOR PRESENTATION
www.thcl.com.au ASX RELEASE (16 th May 2017) PROACTIVE INVESTOR PRESENTATION The Hydroponics Company Limited (ASX: THC) is pleased to advise that Dr Andrew Beehag, Chief Executive Officer of Canndeo Limited,
More informationFlu Watch. MMWR Week 3: January 14 to January 20, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 3: January 14 to January 2, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
More informationSmall-Cap Research. Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report OUTLOOK
Small-Cap Research May 25, 2017 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report DMPI: A New Phase
More informationFY 2014 ANNUAL MANAGEMENT REPORT
THE DEFENSE INTELLIGENCE AGENCY LEADER EVALUATION of DEVELOPMENT and INVESTMENT DIALED IN FY 2014 ANNUAL MANAGEMENT REPORT A report designed to aid in making informed evidence-based decisions when recommending
More informationReal Estate Analysis Report
1Q 2 1Q 21 1Q 22 1Q 23 1Q 24 1Q 25 1Q 26 1Q 27 1Q 28 1Q 29 1Q 21 1Q 211 1Q 212 1Q 213 1Q 214 1Q 215 1Q 216 1Q 217 NLI Research Institute May 22, 217 Real Estate Analysis Report Japanese Property Market
More informationPortfolio Strategy Group
PSG's Weekly Chart Perspective Portfolio Strategy Group Report Date: Monday, September 27, 21 Daily Close UST 1 Year CMT 5 Year History 5. 4.5 4. 3.5 3. 2.5 2. US Recession Sep-5 Dec-5 Mar-6 Jun-6 Sep-6
More informationPortfolio Strategy Group
PSG's Weekly Chart Perspective Portfolio Strategy Group Report Date: Monday, November 15, 21 Daily Close UST 1 Year CMT 5 Year History 5. 4.5 4. 3.5 3. 2.5 2. US Recession Nov-5 Feb-6 May-6 Aug-6 Nov-6
More informationObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationThird Quarter Results to September 30, 2009
Third Quarter Results to September 30, 2009 Shire plc October 30, 2009 Angus Russell Chief Executive Officer Graham Hetherington Chief Financial Officer Michael Cola President, Specialty Pharmaceuticals
More informationTimetable detailed schedule Term 3 and
Term 3 and 4 2017 Welcome to the Term 3 and 4 2017 timetable schedule This timetable forms a detailed schedule to the Academic Calendar Timetable 2017-2019 which can be found on our website. Its purpose
More informationFlu Watch. MMWR Week 4: January 21 to January 27, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 4: January 21 to January 27, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
More information22nd Century Group, Inc. (XXII - $ Buy)
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.47 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
More informationBACIT Limited. July 2015 Factsheet
BACIT Limited KEY DETAILS INVESTMENT METHODOLOGY July 2015 Factsheet Net Assets Inception Date NAV Total Return Since Inception NAV Per Share ( ) Share Price (Mid Market) ( ) Ex-Div (16 July 2015) 474.9m
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationThyrocare Wellness for your Wealth
A quality report by JainMatrix Investments Thyrocare Wellness for your Wealth Date 26 th April 2016 Price range: Rs. 420-446 and Period: 27-29 th April 2016 Advice: BUY with a 2 year perspective Mid Cap
More informationJefferies Healthcare Conference June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More information(GALE-NASDAQ) OUTLOOK
Small-Cap Research November 7, 2013 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Galena Biopharma Inc. Galena: Reported sales from Abstral ahead
More informationQUALITAS MEDICAL GROUP LIMITED. CORPORATE PRESENTATION January 2010
QUALITAS MEDICAL GROUP LIMITED CORPORATE PRESENTATION January 2010 Contents Our Business Corporate Developments Growth Strategies Financial Highlights Summary Business Overview Who We Are Established in
More informationConsumer Wellness in India Growth Ahead
1 Consumer Wellness in India Growth Ahead Indian Health & Wellness industry Valued at over INR 590 bn, growing at CAGR of 18% - 20% p.a. Growth expected to continue. Industry growth being driven by: Increasing
More informationRisk Tolerance and Behavioral Finance
Risk Tolerance and Behavioral Finance September 11, 2017 by Michael Pompian of IMCA We have seen a powerful recovery in asset prices in the wake of the global financial crisis (GFC). We cannot forget,
More informationSmall-Cap Research. Delmar Pharma (DMPI-OTCQB)
Small-Cap Research February 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Delmar Pharma (DMPI-OTCQB) DMPI: Ready to advance VAL-083 to pivotal
More informationNutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS
Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to
More information1Q2005. Hera Group presentation
1Q2005 Hera Group presentation 1 Y2005 has been characterized by a stream of achievements: Corporate Governance A new BoD was appointed in April. Further penetration of the Hera Gas market: 1,500 new clients
More informationDevelopment Bank of Southern Africa Amendment Bill [B ]
Development Bank of Southern Africa Amendment Bill [B 2-2014] Briefing of Standing Committee on Finance National Assembly 8 July 2014 Presenters: Mr Lefentse Radikeledi Director: Asset and Liability Management
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationSirtex Medical Ltd Buy
Research Sirtex Medical Ltd Buy Price: A$16.32 Price Target: A$20.50 ASX: SRX 21 April 2017 Sirtex Medical (SRX) is a global medical device company which targets cancer therapies, with its lead product
More informationMARCH 2014 RESULTS PRESENTATION Madrid, 2014
MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted
More informationSmall-Cap Research. Celator Pharma (CPXX-NASDAQ)
Small-Cap Research June 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Positive top line data reported for
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationInvestor presentation. Bioshares Biotech Summit July 2017
Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationscr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (MBVX - Nasdaq) OUTLOOK ZACKS ESTIMATES
Small-Cap Research August 26, 2016 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 MabVax Therapeutics Holdings, Inc. MBVX: Uplist to Nasdaq
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationMyriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationInvestor Presentation
Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of
More informationLeading Cannabinoid Patient Care in Canada. Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF
Leading Cannabinoid Patient Care in Canada Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF Forward Looking Statements Except for historical information, this presentation contains forward-looking
More informationQ Investor Kit JANUARY-MARCH 2013
Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationAttracting Talent & Driving Growth in Wisconsin
Attracting Talent & Driving Growth in Wisconsin v 2 nd Annual Future Wisconsin Economic Summit Kevin Conroy, Chairman & CEO December 9, 2015 WMC Foundation: Second Annual Future Wisconsin Economic Summit
More informationStrategic Plan: Implementation Work Plan
Healthy Eating Active Living New Hampshire Strategic Plan: Implementation Work Plan July 1, 2011 June 30, Adopted: July 28, 2011 Goal One: Increase the number and effectiveness of community coalitions
More informationSt. Jude Medical Inc (STJ) - Medical Equipment - Deals and Alliances Profile
St. Jude Medical Inc (STJ) - Medical Equipment - Deals and Alliances Profile St. Jude Medical Inc (STJ) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business and market
More informationESM MANAGEMENT COMMENTS ON BOARD OF AUDITORS ANNUAL REPORT TO THE BOARD OF GOVERNORS. for the period ended 31 December 2015
ESM MANAGEMENT COMMENTS ON BOARD OF AUDITORS ANNUAL REPORT TO THE BOARD OF GOVERNORS for the period ended 31 December 2015 2 EUROPEAN STABILITY MECHANISM Dear Chairperson, I would like to thank you for
More informationCOMPONENT TESTS OF CLASS I MILK AND FLUID MILK PRODUCTS PACIFIC NORTHWEST ORDER: 2008 AND 2013
UNITED STATES DEPARTMENT OF AGRICULTURE 1930-220th St. SE, Ste. 102 Agricultural Marketing Service 4835 E. Cactus Rd., Suite 365 Bothell, WA 98021 Dairy Programs Scottsdale, AZ 85254 Phone: (425) 487-6009
More informationInvestment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationSector Update. Rubber Glove. Robust Demand Spills Over to 2010
PP10551/10/2010(025682) 13 January 2010 Jason Yap +60 (3) 9207 7698 Jason.yap@osk.com.my Sector Update Rubber Glove MALAYSIA EQUITY Investment Research Daily News Robust Demand Spills Over to 2010 OVERWEIGHT
More informationSmall-Cap Research. Aevi Genomic Medicine (GNMX-NASDAQ) GNMX: SAGA Misses Primary Endpoint But Data-Within-Data Warrants Optimism OUTLOOK SUMMARY DATA
Small-Cap Research March 27, 2017 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Aevi Genomic Medicine (GNMX-NASDAQ) GNMX: SAGA Misses Primary
More informationHILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
More informationThe Psychology of Trading Tools and Techniques for Minding the Markets by Dr. Brett Steenbarger
The Psychology of Trading Tools and Techniques for Minding the Markets by Dr. Brett Steenbarger Success in the markets, as in life, depends on having a healthy and clear strategy for emotional risk management.
More informationImplementation Status & Results Mali Mali - Multi-sectoral HIV/AIDS Project (P082957)
Public Disclosure Authorized Public Disclosure Authorized The World Bank Implementation Status & Results Mali Mali - Multi-sectoral HIV/AIDS Project (P082957) Operation Name: Mali - Multi-sectoral HIV/AIDS
More information